Aesica Pharmaceuticals - your custom synthesis partner
Aesica is a leading supplier of active pharmaceutical ingredients (APIs) and custom synthesis solutions to the global pharmaceutical and biotechnology industries.
With more than 25 years experience, Aesica has the facility and expertise to take products from the preclinical stage right through to the market place. We provide fully comprehensive services including process development, analytical development, cGMP manufacturing, scale-up and full regulatory support.
Our custom synthesis solutions are cost-effective, incorporate the highest quality and regulatory standards and show our commitment to integrated project management. Our facilities are designed to meet all our customers" r&d and commercial supply needs.
Aesica is granted a licence for manufacturing controlled substances
Aesica Pharmaceuticals, an innovative and service-driven supplier of APIs, finished dosage forms and custom synthesis solutions, announce its licence approval for manufacturing controlled substances.
Aesica's Cramlington, UK site has been recently granted a Home Office licence to allow manufacture and supply of substances listed in Schedule 2 of the Misuse of Drugs Act 1971. Granting of this licence followed a programme of investment carried out to enhance the security of the site and its buildings, and the implementation of special procedures for handling of controlled substances.
These changes allow the Aesica Cramlington site to offer facilities for contract manufacture of controlled active pharmaceutical ingredients in quantities from a few kilogrammes in its GMP pilot plant to tonnes in one of its bulk API plants. The first contract-manufactured controlled drug for one of Aesica's customers is already in production.
Aesica can now offer such controlled drug manufacturing capability at two sites in the UK: Queenborough and Cramlington covering both active ingredient synthesis and manufacture and packaging of finished dosage pharmaceutical forms.
Mr. Adam Sims, Commercial Director of Aesica, said: This is a significant step forward for Aesica in terms of broadening our capabilities in line with our customers" demand..